Janez IlaÅ

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2453844/publications.pdf

Version: 2024-02-01

76	1,805	279701 23	315616 38
papers	citations	h-index	g-index

80	80	80	2200
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recent advances in the synthesis of 2H-1,4-benzoxazin-3-(4H)-ones and 3,4-dihydro-2H-1,4-benzoxazines. Tetrahedron, 2005, 61, 7325-7348.	1.0	154
2	Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. Journal of Medicinal Chemistry, 2020, 63, 884-904.	2.9	126
3	Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 8941-8954.	2.9	99
4	Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site. Journal of Medicinal Chemistry, 2015, 58, 5501-5521.	2.9	92
5	A road map for prioritizing warheads for cysteine targeting covalent inhibitors. European Journal of Medicinal Chemistry, 2018, 160, 94-107.	2.6	80
6	3,4-Dihydro-2H-1,4-benzoxazine Derivatives Combining Thrombin Inhibitory and Glycoprotein IIb/IIIa Receptor Antagonistic Activity as a Novel Class of Antithrombotic Compounds with Dual Function. Journal of Medicinal Chemistry, 2008, 51, 5617-5629.	2.9	59
7	Toward a Novel Class of Antithrombotic Compounds with Dual Function. Discovery of 1,4-Benzoxazin-3(4H)-one Derivatives Possessing Thrombin Inhibitory and Fibrinogen Receptor Antagonistic ActivitiesÂ§. Journal of Medicinal Chemistry, 2005, 48, 3110-3113.	2.9	53
8	N-Phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATP Competitive DNA Gyrase B Inhibitors: Design, Synthesis, and Evaluation. Journal of Medicinal Chemistry, 2015, 58, 6179-6194.	2.9	49
9	Antimicrobial Activity of the Marine Alkaloids, Clathrodin and Oroidin, and Their Synthetic Analogues. Marine Drugs, 2014, 12, 940-963.	2.2	48
10	Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors. European Journal of Medicinal Chemistry, 2017, 130, 171-184.	2.6	43
11	Influence of different classes of crosslinkers on alginate polyelectrolyte nanoparticle formation, thermodynamics and characteristics. Carbohydrate Polymers, 2018, 181, 93-102.	5.1	42
12	Recent progress in the discovery and development of DNA gyrase B inhibitors. Future Medicinal Chemistry, 2018, 10, 1207-1227.	1.1	41
13	ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents. Expert Opinion on Therapeutic Patents, 2019, 29, 171-180.	2.4	41
14	Synthesis and Evaluation of Nâ€Phenylpyrrolamides as DNA Gyraseâ€...B Inhibitors. ChemMedChem, 2018, 13, 186-198.	1.6	40
15	Design, synthesis and biological evaluation of 4,5-dibromo-N-(thiazol-2-yl)-1H-pyrrole-2-carboxamide derivatives as novel DNA gyrase inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 338-349.	1.4	37
16	An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors. European Journal of Medicinal Chemistry, 2019, 167, 269-290.	2.6	36
17	New N -phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity. European Journal of Medicinal Chemistry, 2018, 154, 117-132.	2.6	35
18	New N -phenyl-4,5-dibromopyrrolamides and N -Phenylindolamides as ATPase inhibitors of DNA gyrase. European Journal of Medicinal Chemistry, 2016, 117, 197-211.	2.6	29

#	Article	IF	Citations
19	Structure-activity relationships and molecular docking studies of chromene and chromene based azo chromophores: A novel series of potent antimicrobial and anticancer agents. EXCLI Journal, 2017, 16, 868-902.	0.5	29
20	Inhibition of biofilm formation by conformationally constrained indole-based analogues of the marine alkaloid oroidin. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2530-2534.	1.0	28
21	Exploring protein hotspots by optimized fragment pharmacophores. Nature Communications, 2021, 12, 3201.	5.8	28
22	Targeted Cancer Therapy Using Compounds Activated by Light. Cancers, 2021, 13, 3237.	1.7	28
23	2-Aminoimidazoles in Medicinal Chemistry. Mini-Reviews in Medicinal Chemistry, 2013, 13, 1921-1943.	1.1	27
24	Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores. European Journal of Medicinal Chemistry, 2013, 64, 302-313.	2.6	24
25	Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics, 2014, 15, 487.	1.2	24
26	Novel Potent and Selective Thrombin Inhibitors Based on a Central 1,4-Benzoxazin-3(4H)-one Scaffold. Journal of Medicinal Chemistry, 2008, 51, 2863-2867.	2.9	23
27	Heterocyclic electrophiles as new MurA inhibitors. Archiv Der Pharmazie, 2018, 351, e1800184.	2.1	22
28	Development of Spin-Labeled Probes for Adenosine Receptorsâ€. Journal of Medicinal Chemistry, 2005, 48, 2108-2114.	2.9	21
29	Rational design of balanced dual-targeting antibiotics with limited resistance. PLoS Biology, 2020, 18, e3000819.	2.6	20
30	Advances in the Synthesis of Morpholin-3-ones and Morpholin-2-ones. Synthesis, 2012, 44, 3551-3578.	1.2	19
31	Exploring the Chemical Space of Benzothiazole-Based DNA Gyrase B Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 2433-2440.	1.3	18
32	Towards dual antithrombotic compounds â€“ Balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism. European Journal of Medicinal Chemistry, 2013, 62, 329-340.	2.6	16
33	Dual Escherichia coli DNA Gyrase A and B Inhibitors with Antibacterial Activity. ChemMedChem, 2020, 15, 265-269.	1.6	16
34	Design, synthesis, and biological evaluation of 1â€ethylâ€3â€(thiazolâ€2â€yl)urea derivatives as Escherichia coli DNA gyrase inhibitors. Archiv Der Pharmazie, 2018, 351, 1700333.	2.1	15
35	New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens. European Journal of Medicinal Chemistry, 2021, 213, 113200.	2.6	15
36	Substituted 4-phenyl-2-aminoimidazoles and 4-phenyl-4,5-dihydro-2-aminoimidazoles as voltage-gated sodium channel modulators. European Journal of Medicinal Chemistry, 2014, 74, 23-30.	2.6	13

#	Article	IF	Citations
37	New N-phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors. MedChemComm, 2019, 10, 1007-1017.	3.5	13
38	Design, synthesis and biological evaluation of novel DNA gyrase inhibitors and their siderophore mimic conjugates. Bioorganic Chemistry, 2020, 95, 103550.	2.0	13
39	Novel 1,4-benzoxazine and 1,4-benzodioxine inhibitors of angiogenesis. European Journal of Medicinal Chemistry, 2012, 58, 160-170.	2.6	12
40	Analogues of the marine alkaloids oroidin, clathrodin, and hymenidin induce apoptosis in human HepG2 and THP-1 cancer cells. MedChemComm, 2015, 6, 105-110.	3.5	12
41	Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. European Journal of Medicinal Chemistry, 2017, 139, 232-241.	2.6	12
42	Synthesis and evaluation of anticancer activity of new 9-acridinyl amino acid derivatives. RSC Medicinal Chemistry, 2020, 11, 378-386.	1.7	12
43	Efficient Synthesis of Hydroxy-Substituted 2-Aminobenzo[d]thiazole-6-carboxylic Acid Derivatives as New Building Blocks in Drug Discovery. ACS Omega, 2020, 5, 8305-8311.	1.6	12
44	Design, Synthesis, inâ€...vitro and in silico Characterization of 2â€Quinoloneâ€Łâ€alaninateâ€1,2,3â€triazoles as Antimicrobial Agents. ChemMedChem, 2022, 17, .	1.6	12
45	Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold. European Journal of Medicinal Chemistry, 2012, 50, 255-263.	2.6	11
46	A convenient strategy for synthesizing the Agelas alkaloids clathrodin, oroidin, and hymenidin and their (un)saturated linker analogs. Tetrahedron Letters, 2014, 55, 3999-4001.	0.7	11
47	1,4-Diazepine-2,5-dione ring formation during solid phase synthesis of peptides containing aspartic acid Î²-benzyl ester. Journal of Peptide Science, 2007, 13, 742-748.	0.8	10
48	Thrombin inhibitors with lipid peroxidation and lipoxygenase inhibitory activities. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4705-4709.	1.0	10
49	Chemistry of 2â€Aminoimidazoles. Journal of Heterocyclic Chemistry, 2016, 53, 345-355.	1.4	10
50	Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 1579-1587.	1.4	10
51	Multitarget Antithrombotic Drugs. Current Topics in Medicinal Chemistry, 2011, 11, 2834-2848.	1.0	10
52	Action of Clathrodin and Analogues on Voltage-Gated Sodium Channels. Marine Drugs, 2014, 12, 2132-2143.	2.2	9
53	Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B. European Journal of Medicinal Chemistry, 2017, 125, 500-514.	2.6	9
54	Second-generation 4,5,6,7-tetrahydrobenzo[d]thiazoles as novel DNA gyrase inhibitors. Future Medicinal Chemistry, 2020, 12, 277-297.	1.1	9

#	Article	IF	Citations
55	Hybrid Inhibitors of DNA Gyrase A and B: Design, Synthesis and Evaluation. Pharmaceutics, 2021, 13, 6.	2.0	9
56	Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3251-3256.	1.0	8
57	Synthesis of alkyl N-(4-nitrophenyl)-3/2-oxomorpholine-2/3-carboxylates by rhodium(II) acetate catalyzed Oâ€“H and Nâ€“H carbene insertion. Tetrahedron Letters, 2013, 54, 3341-3343.	0.7	8
58	Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety. MedChemComm, 2014, 5, 197.	3.5	8
59	3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach. Pharmaceuticals, 2016, 9, 2.	1.7	8
60	Design, Synthesis, and Evaluation of Novel Tyrosineâ€Based DNA Gyrase B Inhibitors. Archiv Der Pharmazie, 2017, 350, 1700087.	2.1	8
61	On the Stability and Degradation Pathways of Venetoclax under Stress Conditions. Pharmaceutics, 2020, 12, 639.	2.0	7
62	Practical Synthesis and Application of Halogen-Doped Pyrrole Building Blocks. ACS Omega, 2021, 6, 9723-9730.	1.6	7
63	Peptides and pseudopeptides incorporating <scp>D</scp>â€Pheâ€“Proâ€“Arg and Argâ€“Glyâ€“Asp lead sequences as potential antithrombotic agents. Journal of Peptide Science, 2008, 14, 946-953.	0.8	6
64	Discovery of new ATP-competitive inhibitors of human DNA topoisomerase IIÎ± through screening of bacterial topoisomerase inhibitors. Bioorganic Chemistry, 2020, 102, 104049.	2.0	6
65	A New Cellâ€Based Alâ€2â€Mediated Quorum Sensing Interference Assay in Screening of LsrKâ€Targeted Inhibitors. ChemBioChem, 2020, 21, 1918-1922.	1.3	6
66	Triterpenoid profile and bioactivity study of Oenothera maritima. Phytochemistry Letters, 2015, 13, 324-329.	0.6	5
67	Selective DNA Gyrase Inhibitors: Multi-Target in Silico Profiling with 3D-Pharmacophores. Pharmaceuticals, 2021, 14, 789.	1.7	5
68	The synthesis of alternative diketopiperazines as potential RGD mimetics. Journal of Peptide Science, 2006, 12, 663-669.	0.8	4
69	A pentacyclic condensation product from 2,4-dimethyl-7-nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid. Tetrahedron Letters, 2008, 49, 222-225.	0.7	4
70	Studies towards the Synthesis of Alkyl Nâ€(4â€Nitrophenyl)â€3/2â€oxomorpholineâ€2/3â€carboxylates. Helvetica Chimica Acta, 2013, 96, 2160-2172.	1.0	4
71	Discovery of d-amino acid oxidase inhibitors based on virtual screening against the lid-open enzyme conformation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1693-1698.	1.0	4
72	Synthesis and Evaluation of Spumigin Analogues Library with Thrombin Inhibitory Activity. Marine Drugs, 2018, 16, 413.	2.2	4

#	Article	IF	Citations
73	Ring Opening of 2â€(Benzylamino)â€2Hâ€1,4â€benzoxazinâ€3(4H)â€ones and 2â€Bromoâ€2Hâ€1,4â€benzoxazinâ€3(4H)â€ones. Helvetica Chimica Acta, 2008, 91, 654-664.	1.0	3
74	Synthesis and antiproliferative activity of 2-(([1,2,4]triazolo[4,3-b]-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td (pyridazin-6-yloxy)met 2011, 309-322.	0.3	3
75	Recent Advances in the Synthesis of 2H-1,4-Benzoxazin-3-(4H)-ones and 3,4-Dihydro-2H-1,4-benzoxazines. ChemInform, 2005, 36, no.	0.1	1
76	Novel Thrombin Inhibitors Incorporating Weakly Basic Heterobicyclic P1-Arginine Mimetics: Optimization via Modification of P1 and P3 Moieties.. ChemInform, 2004, 35, no.	0.1	0